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Appraisals Critically Appraised Paper
Summary of: Ferrer M, Valencia M, Nicolas JM, Bernadich 
O, Badia JR and Torres A (2006): Early noninvasive 
ventilation averts extubation failure in patients at risk. A 
randomized trial. American Journal of Respiratory and 
Critical Care Medicine 173: 164–170 [Prepared by Mark 
Elkins, Editorial Board Member.]
Question:  For patients at high risk of respiratory 
failure after extubation, does the early implementation 
of non-invasive positive pressure ventilation (NPPV) 
avert respiratory failure and reduce mortality? Design:  
Randomised, controlled trial with concealed allocation. 
Setting:  Participants were recruited from two intensive 
care units. Patients: Patients intubated for at least 48 hours 
who tolerated a spontaneous breathing trial were eligible if 
they had at least one of the following risk factors for post-
extubation respiratory failure: age over 65 years; cardiac 
failure as the cause of intubation; an Acute Physiology 
and Chronic Health Evaluation (APACHE)-II score greater 
than 12 on the day of extubation. Exclusion criteria were 
contraindications to NPPV and orders against resuscitation. 
Eight eligible patients refused to participate. The remaining 
162 were randomised to intervention (n = 79) or control (n 
= 83) groups. Interventions:  Immediately after extubation, 
the intervention group received NPPV for 24 hours, 
followed by oxygen via a Venturi mask. The control group 
received oxygen via a Venturi mask after extubation. Both 
groups were otherwise managed according to the clinical 
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protocols of each unit. Outcomes:  Respiratory failure in 
the first three days, mortality in the intensive care unit, and 
90-day survival. Respiratory failure was defined as at least 
two of the following: respiratory acidosis; hypoxaemia 
at an inspired oxygen fraction of 0.5 or more; respiratory 
rate > 35/minute; decreased consciousness, agitation or 
diaphoresis; and respiratory muscle fatigue or increased 
work of breathing. A subgroup analysis was performed 
based on the presence of hypercapnia during the spontaneous 
breathing trial. Results:  Compared with the control group, 
respiratory failure was less frequent (Relative Risk 0.5, 95% 
confidence interval (CI) 0.3 to 0.9). This indicates that the 
number of patients that needed to be treated (NNT) with 
early NPPV to prevent one case of respiratory failure was 
6 (95% CI 3 to 36). Mortality in the intensive care unit was 
significantly lower in the NPPV group, with the NNT to 
prevent one death being 8 (95% CI 5 to 30). In the subgroup 
analysis of those with hypercapnia during the spontaneous 
breathing trial, this benefit was greater (NNT 6, 95% CI 3 
to 61). Survival to 90 days showed no significant difference 
between the NPPV and control groups overall. Among the 
subgroup with hypercapnia during the spontaneous breathing 
trial, however, the difference in survival was significant 
(NPPV 85% vs control 50%, p = 0.006). Conclusion: 
NPPV for 24 hours post-extubation in patients at high risk 
of respiratory failure reduced the risk of early respiratory 
failure and mortality. [Relative Risk and NNT calculated by 
CAP Editor from data in paper.]
Commentary
Non-invasive ventilation (NIV) has become standard 
treatment for patients with acute hypercapnic exacerbations 
of COPD. Improved survival is attributed predominantly 
to the avoidance of prolonged endotracheal intubation, 
reducing the risk of infective complications and organ 
dysfunction. Furthermore, recent literature demonstrates 
improved survival when NIV is used to facilitate early 
extubation in patients weaning from mechanical ventilation, 
although a significant proportion of patients included in 
these trials had chronic respiratory disease.
More recently, studies have evaluated NIV as a potential 
therapy to prevent re-intubation and its associated 
complications following extubation failure. The largest trial 
(Esteban et al 2004) used NIV as a recovery strategy in 
patients who developed respiratory failure within 48 hours 
after extubation. Results showed increased mortality in NIV 
treated patients compared to those treated with standard 
medical care. This was linked to a longer time between the 
development of respiratory failure and re-intubation in the 
NIV group. However, a secondary analysis revealed a trend 
towards improved survival in NIV-treated patients with 
COPD.
The current study applied NIV immediately after extubation 
in patients with an increased risk of developing respiratory 
failure. NIV was associated with reduced risk of respiratory 
failure and improved ICU mortality but did not affect 
90-day survival. However, NIV reduced ICU and 90-day 
mortality in those patients who developed hypercapnia 
during their spontaneous breathing trial. Unsurprisingly, 
98% of this group had chronic respiratory disease. Rightly 
the authors recommend further confirmatory studies, but 
given its proven benefit in avoiding and facilitating early 
liberation from invasive mechanical ventilation, it should 
probably not surprise us that early NIV is beneficial in this 
patient group.
There is however some room for caution. In such studies, 
NIV is applied in a ‘standardised’ fashion, in centres 
with significant NIV experience or following extensive 
educational programs. This ‘structure’ is a crucial component 
of the therapy, and needs to be put in place if potential 
benefits are to be realised by individual centres.
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